Table 5.

The ongoing (active, not recruiting) clinical trials with anti-OX40 mAbs (Date: 05/02/2019).

NCT number and title of study	Intervention	Condition
NCT01862900—Stereotactic body radiation and monoclonal antibody to OX40 (MEDI6469) in breast cancer patients with metastatic lesions	MEDI6469 (murine anti-OX40 agonist IgG1)	Metastatic breast cancer; liver and lung metastases;
NCT02274155—Anti-OX40 antibody in head and neck cancer patients	MEDI6469 (murine anti-OX40 agonist IgG1)	Head and neck cancer
NCT02559024—Anti-OX40 antibody (MEDI6469) in patients with metastatic colorectal cancer	MEDI6469 (murine anti-OX40 agonist IgG1)	Colorectal neoplasms
NCT02315066—Study of OX40 agonist PF-04518600 alone and in combination with 4-1BB agonist PF-05082566	PF-04518600 (fully human anti-OX40 agonist IgG2); PF-05082566	Neoplasms
NCT02410512—A study to assess the safety and pharmacokinetics of MOXR0916 and atezolizumab in participants with locally advanced or metastatic solid tumors	MOXR0916 (humanized anti-OX40 agonist IgG1); atezolizumab (anti-PD-L1 mAb)	Neoplasms
NCT02221960—A phase 1 study to evaluate MEDI6383 alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors	MEDI6383 (OX40L fusion protein); MEDI4736 (durvalumab)	Recurrent or metastatic solid tumors
NCT02705482—A study to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with advanced solid tumors	MEDI0562 (humanized anti-OX40 agonist IgG4); tremelimumab; durvalumab	Select advanced solid tumors
NCT02923349—A phase 1/2, open-label, dose-escalation, safety study of INCAGN01949 in subjects with advanced or metastatic solid tumors	INCAGN01949 (fully human anti-OX40 agonist antibody, IgG1)	Advanced malignancies metastatic cancer
NCT03241173—A study exploring the safety and efficacy of INCAGN01949 in combination with immune therapies in advanced or metastatic malignancies	INCAGN01949 (fully human anti-OX40 agonist antibody, IgG1); nivolumab; ipilimumab	Advanced malignancies